| 9.73 Data as of May 21 |  -0.04 / -0.41%Today’s Change | 5.65 Today|||52-Week Range 11.34 | +31.31% Year-to-Date |
| Nektar Posts Wider Loss, Maintains View - Analyst Blog May 15 / Zacks.com | Nektar Therapeutics Increases Sales but Misses Estimates on Earnings May 10 / MotleyFool.com |
| Previous close | 9.77 |
| Today’s open | 9.74 |
| Day’s range | 9.50 - 9.87 |
| Volume | 614,472 |
| Average volume (3 months) | 892,961 |
| Market cap | $1.1B |
| Dividend yield | -- |
| Earnings growth (last year) | -26.05% |
| Earnings growth (this year) | +31.40% |
| Earnings growth (next 5 years) | +16.00% |
| Revenue growth (last year) | +13.59% |
| P/E ratio | NM |
| Price/Sales | 10.48 |
| Price/Book | 23.95 |
| Today’s change | Today’s % change | |
|---|---|---|
| LXRXLexicon Pharmaceutic... | -0.01 | -0.46% |
| AMRNAmarin Corporation P... | -0.07 | -0.99% |
| BRLIBio-Reference Labora... | +0.35 | +1.16% |
| EXELExelixis Inc | +0.12 | +2.67% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.44 |
| Annual revenue (last year) | $81.2M |
| Annual profit (last year) | -$171.9M |
| Net profit margin | -211.67% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Howard W. Robin |
Chief Financial Officer & Senior Vice President John Nicholson |
Corporate headquarters San Francisco, California |
.
